AUROPHARMA
524804Announcement under Regulation 30 (LODR)-Acquisition
Intimation of incorporation of a new wholly owned subsidiary by the name of Ávogent Lifesciences Private Limited'' by Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.
Aurobindo Pharma Ltd is a leading Indian integrated pharmaceutical company, engaged in the research, development, manufacturing, and marketing of generic pharmaceuticals and active pharmaceutical ingredients (APIs). Headquartered in Hyderabad, India, the company has a significant global presence with operations in over 150 countries and a robust product portfolio spanning antibiotics, antiretrovirals, cardiovascular, central nervous system, gastroenterology, anti-diabetics, and more.
Announcement under Regulation 30 (LODR)-Acquisition
Intimation of incorporation of a new wholly owned subsidiary by the name of Ávogent Lifesciences Private Limited'' by Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.
Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)
Submission of Press Release.
Completion Of US FDA Inspection At Unit-VI Of Apitoria Pharma Private Limited, A Wholly Owned Subsidiary Of The Company
Intimation of completion of US FDA inspection at Unit-VI of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Submission of Voting Results and Scrutinizer''s Report of 39th AGM of the Company held on August 27, 2026.
Shareholder Meeting / Postal Ballot-Outcome of AGM
Submission of proceedings of 39th Annual General Meeting of the Company held on 27th August, 2026.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Participation in Investor/ Analyst meet held on September 1-2, 2026 in Hong Kong
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Investor/ Analyst meet scheduled on September 1, 2026.
Completion Of US FDA Inspection At Lannett Company LLC, A Wholly Owned Subsidiary Of Aurobindo Pharma USA, Inc.
Intimation of completion of US FDA inspection at Lannett Company LLC., a wholly owned subsidiary of Aurobindo Pharma, USA Inc.
Completion Of US FDA Inspection At Auro Peptides Ltd, A Subsidiary/Business Arm Of The Company.
Intimation of completion of US FDA inspection at Auro Peptides Limited, a subsidiary of the Company.
Classification Of US FDA Inspection At Raleigh Plant, North Carolina, Owned By Aurolife Pharma LLC, A Wholly Owned Step-Down Subsidiary Of The Company, As Voluntary Action Indicated (VAI)
Intimation of classification of US FDA inspection at Raleigh Plant, North Carolina, owned by Aurolife LLF, a wholly owned step down subsidiary of the Company, as Voluntary Actioin Indicated (VAI).
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of participation of officials of the Company in investors / analysts meet to be held on August 19, 2026
Unit I Of Eugia Pharma Specialities Ltd. Received A Warning Letter From US FDA
Intimation of receipt of warning letter from US FDA by Unit 1 of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company.
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Submission of transcript of the earning call on the unaudited financial results for the quarter ended June 30, 2026.
Announcement under Regulation 30 (LODR)-Acquisition
Intimation of incorporation of a new wholly owned subsidiary.
Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of copies of notice published by the Company on August 7, 2026 in Business Standard and Nava Telangana regarding special window for re-lodgement of transfer requests of physical shares.
Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of copies of newspaper advertisements of the financial results of the Company for the first quarter ended June 30, 2026 as published in Business Standard and Nava Telangana on August 7, 2026.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of participation by the officials of the Company in the Investor/Analyst Meet to be held on August 11 to 13, 2026 in Singapore & Hong Kong
Announcement under Regulation 30 (LODR)-Restructuring
Intimation of proposal of merger of two wholly owned stepdown subsidiaries with a wholly owned subsidiary.
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Submission of Press Release on financial results of the Company for the first quarter ended June 30, 2026.
Announcement under Regulation 30 (LODR)-Investor Presentation
Submission of investor presentation.
Board Meeting Outcome for Outcome Of The Board Meeting Held On August 5, 2026
The Board of Directors of the Company at its meeting held today, August 5, 2026, has, inter alia, considered and approved: a) the standalone and consolidated Unaudited Financial Results of the Company for the first quarter ended June 30, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Reports issued by the Statutory Auditors. b) a proposal to file a Scheme of Amalgamation for merger of Eugia Steriles Private Limited and Eugia SEZ Private Limited, wholly owned step-down subsidiaries of the Company with Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company, with Hon'ble NCLT, Hyderabad, that has been approved by the Board of Directors of the respective companies and also the Company.
Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of copies of notice published in newspapers.
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Confirmation of dispatch of letter to the shareholders who have not registered their email ids, providing weblink for integrated Annual Report 2025-26.
Business Responsibility and Sustainability Reporting (BRSR)
Submission of BRSR for FY 2025-26.
Notice Of 39Th Annual General Meeting
Submission of Notice of 39th Annual General Meeting of the Company to be held August 27, 2026.
Reg. 34 (1) Annual Report.
Submission of Integrated Annual Report 2025-26
Aurobindo Pharma Ltd
About
Aurobindo Pharma Ltd is a leading Indian integrated pharmaceutical company, engaged in the research, development, manufacturing, and marketing of generic pharmaceuticals and active pharmaceutical ingredients (APIs). Headquartered in Hyderabad, India, the company has a significant global presence with operations in over 150 countries and a robust product portfolio spanning antibiotics, antiretrovirals, cardiovascular, central nervous system, gastroenterology, anti-diabetics, and more.
The company's manufacturing network includes more than 20 plants approved by international regulatory agencies such as US FDA, UK MHRA, and EU authorities, supporting its commitment to quality and compliance. With a diversified product base and consistent investments in research and development, Aurobindo Pharma is positioned as a major exporter of formulations and APIs, and is counted among the top 2 pharmaceutical companies by volume in the US generics market as of 2024.
Business Model & Strategy
Aurobindo Pharma derives revenues primarily from the manufacture and sale of generic pharmaceutical formulations and APIs for global markets including the US, Europe, and emerging economies. The company follows a vertically integrated structure, producing both APIs and finished dosage forms, which enables cost efficiency and supply security. Major business segments include formulations (oral solids, injectables, specialty drugs) and APIs, with differentiated focus on complex generics, biosimilars, and specialty segments such as oncology and injectables.
Growth strategies are centered on expanding the product pipeline through in-house R&D, entering high-growth therapeutic categories, increasing market share in regulated markets, and pursuing value-accretive acquisitions. The company is accelerating investments in differentiated and specialty products, digital transformation initiatives, and expanding capacity with new, US FDA-compliant facilities. Partnerships, out-licensing, and geographic diversification remain key components of its future business model.
Management Overview
11 MembersMr.Mangalam Ramasubramanian Kumar
Non-Executive - Independent Director-ChairpersonMr.Nityananda Reddy Kambam
Executive Director-MDSanthanamSubramanian
Chief Financial OfficerMr.Madan Mohan Reddy Mettu
Executive DirectorMr.Venkata Ramprasad Reddy Penaka
Non-Executive - Non Independent DirectorMr.Sarath Chandra Reddy Penaka
Non-Executive - Non Independent DirectorMr.Girish Paman Vanvari
Non-Executive - Independent DirectorMr.Santanu Mukherjee
Non-Executive - Independent DirectorMr.Satakarni Makkapati
Non-Executive - Non Independent DirectorMrs.Deepali Pant Joshi
Non-Executive - Independent DirectorBAdiReddy
Company Secretary & Compliance OfficerAwards & Recognition
5 Awards- Ranked among the Top 10 Indian pharmaceutical companies by revenue (2024, multiple industry reports)
- Awarded ‘Best API Supplier’ (2024, CPHI India Pharma Awards)
- Achieved multiple US FDA, UK MHRA and EU GMP approvals for manufacturing sites (2023–2025)
- Included in S&P ESG Index for commitment to sustainability (2024)
- Recognized by Dun & Bradstreet as a leading Indian exporter (2024)
Market Information
Company Timeline
38+ Years of Excellence | 8 Major Milestones
Aurobindo Pharma Ltd founded in Hyderabad, India
Initial Public Offering (IPO) listed on Indian stock exchanges
Commenced US FDA-certified API exports
Expanded into finished dosage formulations for US and EU markets
Acquisition of Actavis’ generic operations in Western Europe from Teva Pharma
Entered oncology and hormonal segments; launched biosimilar R&D division
US FDA approval for multiple injectable facilities in India
Awarded 'Best API Supplier' at CPHI India Pharma Awards; Expansion of digital transformation and R&D investments
The Next Evolution
Contact Information
Registered Office
Plot No.2, Maitrivihar, Ameerpet
Tel: 040-66725000 / 23736370,
Fax: 040-67074059 / 23747340,
Email: cs@aurobindo.com; investorgrievances@aurobindo.com ; info@aurobindo.com
Website: aurobindo.com
Registrars
KFin Technologies Ltd
Tel: 040 - 67162222 / 67161500 / 18003454001
Email: einward.ris@karvy.com
Corporate Actions
28| Purpose | Ex Date | Record Date | BC Start | BC End |
|---|---|---|---|---|
Buy Back of Shares | 17 Apr 2026 Friday | 17 Apr 2026 Friday | - | - |
Interim Dividend ₹4 per share | 08 Aug 2025 Friday | 08 Aug 2025 Friday | - | - |
Buy Back of Shares | 30 Jul 2024 Tuesday | 30 Jul 2024 Tuesday | - | - |
Interim Dividend ₹1.50 per share | 20 Feb 2024 Tuesday | 20 Feb 2024 Tuesday | - | - |
Interim Dividend ₹3 per share | 20 Nov 2023 Monday | 20 Nov 2023 Monday | - | - |
Interim Dividend ₹3 per share | 17 Feb 2023 Friday | 17 Feb 2023 Friday | - | - |
Interim Dividend ₹4.50 per share | 06 Jun 2022 Monday | 07 Jun 2022 Tuesday | - | - |
Interim Dividend ₹1.50 per share | 18 Feb 2022 Friday | 21 Feb 2022 Monday | - | - |
Interim Dividend ₹1.50 per share | 17 Nov 2021 Wednesday | 18 Nov 2021 Thursday | - | - |
Interim Dividend ₹1.50 per share | 27 Aug 2021 Friday | 30 Aug 2021 Monday | - | - |
Interim Dividend ₹1.50 per share | 22 Feb 2021 Monday | 23 Feb 2021 Tuesday | - | - |
Interim Dividend ₹1.25 per share | 23 Nov 2020 Monday | 24 Nov 2020 Tuesday | - | - |
Interim Dividend ₹1.25 per share | 21 Aug 2020 Friday | - | 25 Aug 2020 Tuesday | 27 Aug 2020 Thursday |
Interim Dividend ₹1.75 per share | 17 Feb 2020 Monday | 18 Feb 2020 Tuesday | - | - |
Interim Dividend ₹1.25 per share | 21 Nov 2019 Thursday | 23 Nov 2019 Saturday | - | - |
Interim Dividend ₹1.25 per share | 15 Feb 2019 Friday | 19 Feb 2019 Tuesday | - | - |
Interim Dividend ₹1.25 per share | 20 Nov 2018 Tuesday | 22 Nov 2018 Thursday | - | - |
Interim Dividend ₹1 per share | 20 Feb 2018 Tuesday | 21 Feb 2018 Wednesday | - | - |
Interim Dividend ₹1.50 per share | 21 Nov 2017 Tuesday | 22 Nov 2017 Wednesday | - | - |
Interim Dividend ₹1.25 per share | 08 Jun 2017 Thursday | 09 Jun 2017 Friday | - | - |
Interim Dividend ₹1.25 per share | 24 Nov 2016 Thursday | 25 Nov 2016 Friday | - | - |
Interim Dividend ₹0.70 per share | 09 Jun 2016 Thursday | 10 Jun 2016 Friday | - | - |
Interim Dividend ₹0.70 per share | 18 Feb 2016 Thursday | 22 Feb 2016 Monday | - | - |
Interim Dividend ₹0.60 per share | 19 Nov 2015 Thursday | 20 Nov 2015 Friday | - | - |
Interim Dividend ₹0.50 per share | 21 Aug 2015 Friday | - | 25 Aug 2015 Tuesday | 27 Aug 2015 Thursday |
Bonus issue 1:1 | 20 Jul 2015 Monday | 21 Jul 2015 Tuesday | - | - |
Interim Dividend ₹1 per share | 08 Jun 2015 Monday | 09 Jun 2015 Tuesday | - | - |
Interim Dividend ₹2 per share | 16 Feb 2015 Monday | 18 Feb 2015 Wednesday | - | - |
₹96,836 Cr.
₹1,683
₹1,717 / 1,016
26.47
₹658.4
2.56
₹63.59
₹1.00
N/A
Manage Ratio
FINANCIALS
| Annual Results | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | - | - | - | 19,679 | 23,185 | 25,155 | 23,776 | 25,146 | 29,559 | 32,346 | 34,145 | 27,219 |
| Expenses | - | - | - | 16,503 | 19,400 | 20,571 | 20,244 | 22,522 | 24,970 | 27,248 | 28,970 | 22,965 |
| Profit | - | - | - | 2,365 | 2,830 | 5,334 | 2,647 | 1,928 | 3,169 | 3,484 | 3,503 | 2,863 |
| Tax | - | - | - | 727 | 914 | 2,010 | 726 | 685 | 1,211 | 1,583 | 1,609 | 1,282 |
| EPS | - | - | - | 40 | 48 | 91 | 45 | 33 | 54 | 60 | 60 | 17.86 |
| Ratios | - |
Cash Flow
Consolidated Figures in Rs. Crores
| Annual Balance Sheet | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | - | - | - | 26,454 | 28,926 | 33,854 | 33,922 | 39,890 | 45,072 | 49,785 | 58,502 | - |
| Equity And Liabilities | - | - | - | 26,454 | 28,926 | 33,854 | 33,922 | 39,890 | 45,072 | 49,785 | 58,502 | - |
Shareholding Pattern
Numbers in Percentages
| Quarterly SHP Announcement Date | Mar 2016 12 Apr '16 | Mar 2017 31 Mar '17 | Mar 2018 31 Mar '18 | Mar 2019 12 Apr '19 | Mar 2020 29 Apr '20 | Mar 2021 17 Apr '21 | Mar 2022 16 Apr '22 | Mar 2023 14 Apr '23 | Mar 2024 05 Apr '24 | Mar 2025 15 Apr '25 | Mar 2026 17 Apr '26 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Goverments | - | - | - | - | - | - | - | - | - | - | - | - |
| Promoter And Promoter Group | - | - | - | 51.87% | 52.01% | 51.94% | 51.83% | 51.83% | 51.83% | 51.82% | 51.82% | - |
| Non Institutions | - | - | - | 12.97% | 13.16% | 10.45% | 9.86% | 10.05% | 6.87% | 6.61% | 7.08% | - |
| FII | - | - | - | - | - | - | - | 23.03% | 18.02% | 15.33% | 15.24% | - |
| DII | - | - | - | - | - | - | - | 15.08% | 23.28% | 26.23% | 25.87% | - |
| Total | - | - | - | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - |
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd is a leading Indian integrated pharmaceutical company, engaged in the research, development, manufacturing, and marketing of generic pharmaceuticals and active pharmaceutical ingredients (APIs). Headquartered in Hyderabad, India, the company has a significant global presence with operations in over 150 countries and a robust product portfolio spanning antibiotics, antiretrovirals, cardiovascular, central nervous system, gastroenterology, anti-diabetics, and more.
The company's manufacturing network includes more than 20 plants approved by international regulatory agencies such as US FDA, UK MHRA, and EU authorities, supporting its commitment to quality and compliance. With a diversified product base and consistent investments in research and development, Aurobindo Pharma is positioned as a major exporter of formulations and APIs, and is counted among the top 2 pharmaceutical companies by volume in the US generics market as of 2024.
Aurobindo Pharma derives revenues primarily from the manufacture and sale of generic pharmaceutical formulations and APIs for global markets including the US, Europe, and emerging economies. The company follows a vertically integrated structure, producing both APIs and finished dosage forms, which enables cost efficiency and supply security. Major business segments include formulations (oral solids, injectables, specialty drugs) and APIs, with differentiated focus on complex generics, biosimilars, and specialty segments such as oncology and injectables.
Growth strategies are centered on expanding the product pipeline through in-house R&D, entering high-growth therapeutic categories, increasing market share in regulated markets, and pursuing value-accretive acquisitions. The company is accelerating investments in differentiated and specialty products, digital transformation initiatives, and expanding capacity with new, US FDA-compliant facilities. Partnerships, out-licensing, and geographic diversification remain key components of its future business model.
Ranked among the Top 10 Indian pharmaceutical companies by revenue (2024, multiple industry reports)
Awarded ‘Best API Supplier’ (2024, CPHI India Pharma Awards)
Achieved multiple US FDA, UK MHRA and EU GMP approvals for manufacturing sites (2023–2025)
Included in S&P ESG Index for commitment to sustainability (2024)
Recognized by Dun & Bradstreet as a leading Indian exporter (2024)
Aurobindo Pharma Ltd founded in Hyderabad, India
Initial Public Offering (IPO) listed on Indian stock exchanges
Commenced US FDA-certified API exports
Expanded into finished dosage formulations for US and EU markets
Acquisition of Actavis’ generic operations in Western Europe from Teva Pharma
Entered oncology and hormonal segments; launched biosimilar R&D division
US FDA approval for multiple injectable facilities in India
Awarded 'Best API Supplier' at CPHI India Pharma Awards; Expansion of digital transformation and R&D investments
Peer Comparison
| S.No. | Company Name | CMP (₹) | Market Cap (₹ Cr) | Div Yld (%) | NP Qtr (₹ Cr) | Qtr Profit Var (%) | Sales Qtr (₹ Cr) | Qtr Sales Var (%) | ROCE (%) | ROE (%) | Book Value (₹) | EPS TTM (₹) | TTMPE Ratio (₹) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon
Heatmap View
Premium Feature| Company | CMP (₹) | MCap (₹ Cr) | EPS TTM (₹) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Financial Ratios
Premium Feature| Company Name | P/E (TTM) | EPS (₹) | D/E | NPM | GPM | ROE (%) | ROCE (%) | P/B | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon